comprehensive -WSS

comprehensive

author：explore 2025-10-01 02:15:57 - browse：4169

Patient treated with Impella in the heart. -- health tech coverage from STAT — Abiomed, which was bought by Johnson & Johnson late last year for $16.6 billion, sells devices for heart failure patients as well as patient monitoring software. Business Wire

The Food and Drug Administration is following through on its promise to regulate more health software tools, starting with a public reprimand of Johnson & Johnson’s heart pump company, Abiomed.

Abiomed, which was bought by Johnson & Johnson late last year for $16.6 billion, sells devices for heart failure patients as well as patient monitoring software. The FDA published a warning letter on Wednesday telling the company it should have submitted its software for approval before putting it on the market. The agency also took issue with Abiomed’s failure to report various problems with its heart pumps.

The letter comes a year after the Food and Drug Administration announced its intention to regulate more health software tools, sending the industry into an uproar.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Prescription digital therapeutics are key to pharma’s future

WSS

Take antibiotics after sex, CDC recommends for certain risk groups

A letter from the executive editor: The 2023 STATUS List

A letter from the executive editor: The 2023 STATUS List

ASCO Takeaways: Winners, snoozers, and the art of cancer care

'Screen and refer' systems are hurting patients

Medicare Advantage's lean provider networks lead CMS complaints

explore

comprehensive

knowledge

Supreme Court strikes down use of affirmative action

A new initiative will help leaders fight the next pandemic

What does generative AI mean for health care? We asked experts

Grandmother of French teen shot dead by police officer pleads with rioters to stop the violence

Medical records are filled with copy

Trump’s hydroxychloroquine hype: a risk to my treatment and to him

Psychedelics group wrestles with new pharma identity

AstraZeneca lung cancer study comes in below expectations

State Dept. review finds Biden bears some blame for Afghanistan failures

Undocumented workers face uncertainty as immigration law takes effect in Florida

hotspot

UnitedHealth CEO's Medicaid comments send insurer stocks diving

AstraZeneca lung cancer study comes in below expectations

Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

ASCO Takeaways: Winners, snoozers, and the art of cancer care

Skip the lead apron during X

A new initiative will help leaders fight the next pandemic

knowledge

focus

focus

entertainment